<DOC>
	<DOCNO>NCT02127437</DOCNO>
	<brief_summary>LIPS study ( Lanreotide In Polycystic kidney disease Study ) prospective randomize double blind placebo control study . The main objective prove lanreotide , somatostatin analog , able reduce glomerular filtration rate decline 3 year least 30 % . Cardiovascular outcome , blood pressure , quality life safety among secondary outcome . The study , include 180 ADPKD patient , schedule start early 2014 . An equal number patient chronic kidney disease stage 2 ( 90 patient GFR 89 60 ml/mn/1.73 m2 ) chronic kidney disease stage 3 ( 90 patient GFR 59 30 ml/mn/1.73 m2 ) include . The primary endpoint ( GFR decline ) assess repeated measure , overall population well two GFR stratus .</brief_summary>
	<brief_title>Lanreotide In Polycystic Kidney Disease Study</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>autosomal dominant polycystic kidney disease ( clinical , familial , image ground ) measure GFR : 30 89 ml/mn/1.73m2 age &gt; 18 affiliated health insurance write informed consent iohexol /iodine allergy diabetes mellitus associate nephropathy suspect evolutive recent malignant disease ( previous 5 year ) cholelithiasis uncontrolled hypertension ( BP &gt; 160/100 mmHg ) cardiac failure grade III IV accord NYHA ( New York Heart Association ) classification liver failure psychiatric illness pregnancy , lactation , lack contraception use somatostatin analog last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Autosomal dominant polycystic kidney disease ,</keyword>
	<keyword>Glomerular filtration rate ,</keyword>
	<keyword>Somatostatin ,</keyword>
	<keyword>lanreotide</keyword>
</DOC>